Predicting COVID-19 vaccination response in populations who are immunosuppressed

Lancet Rheumatol. 2023 Aug;5(8):e431-e432. doi: 10.1016/S2665-9913(23)00185-6. Epub 2023 Jul 24.

Authors

Katie Bechman¹, Mark D Russell¹, James B Galloway²

Affiliations

¹ Centre for Rheumatic Diseases, King's College London SE5 9RJ, UK.
² Centre for Rheumatic Diseases, King's College London SE5 9RJ, UK. Electronic address: james.galloway@kcl.ac.uk.

PMID: 38251570
DOI: 10.1016/S2665-9913(23)00185-6

No abstract available

MeSH terms

COVID-19 Vaccines* / therapeutic use
COVID-19* / prevention & control
Humans
Immunocompromised Host

Substances

COVID-19 Vaccines